Vivani Medical VANI
- Market cap
- $100.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −26.5%
Vivani Medical's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $4.4M+15% | $4.7M+6% | $3.7M−6% | $3.5M−9% | $4.2M−5% | $4.3M−9% | $4.2M+13% | $4.8M+36% | $4.5M+8% | $4.6M+8% | $4.4M+4% | $4.5M−6% |
| SG&A | $2.7M+71% | $1.5M−55% | $2.5M−6% | $2.2M−31% | $2.1M−22% | $2.2M+43% | $2.3M−6% | $2.7M+25% | $2.2M+5% | $2.2M+1% | $2.4M+4% | $2.4M−11% |
| −$7.1M+31% | −$6.2M−20% | −$6.2M−6% | −$5.7M−19% | −$6.3M−12% | −$6.5M+4% | −$6.6M+5% | −$7.5M+31% | −$6.7M+7% | −$6.8M+5% | −$6.8M+4% | −$6.9M−8% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$6.8M | −$6M−17% | −$6M−4% | −$5.4M−18% | −$6M−11% | −$6M+0% | −$6.3M+4% | −$7.1M+33% | −$6.5M+8% | −$6.6M+10% | −$6.8M+8% | −$6.4M−11% |
| −$0.13 | −$0.12 | −$0.12−100% | −$0.10−23% | −$0.11−15% | −$0.11−8% | −$0.11−8% | −$0.12+20% | −$0.11+0% | −$0.09−18% | −$0.08−27% | −$0.07−42% | |
| 50.8M+132023% | 51.1M | 52.2M+102751% | 55M+8% | 55.2M+9% | 57.4M+12% | 59.2M+14% | 59.2M+8% | 59.7M+8% | 71.3M+24% | 81.3M+37% | 87.1M+47% |
EPS, diluted: 10 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Vivani Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VANIVivani Medical | $100.1M | n/m | n/a | n/m | n/m | n/m | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| Peer median | $94M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Vivani Medical
Each number over time
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .